

MEDISCA® NETWORK INC. TECHNICAL SUPPORT SERVICES FORMULATION CHEMISTRY DEPARTMENT TOLL-FREE: 866-333-7811

TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

Addendum to the Assignment of Beyond-Use Dates for Sterile Preparations

USP <797> GENERAL GUIDELINES FOR ASSIGNING BEYOND-USE DATE LIMITS

USP Chapter <797> distinguishes three categories of CSPs: Category 1, Category 2, and Category 3, primarily based on the state of environmental control under which they are compounded, the probability for microbial growth during the time they will be stored, and the time period within which they must be used.

- 1. Category 1 CSPs: compounded under the least controlled environmental conditions.
- 2. Category 2 CSPs: require more environmental controls and testing than Category 1 CSPs.
- 3. Category 3 CSPs: undergo sterility testing, supplemented by endotoxin testing when applicable, and have more requirements than Category 2 CSPs for personnel qualification, use of sterile garb, use of sporicidal disinfectants, frequency of environmental monitoring, and stability determination.

Table 1: Compounded Sterile Preparations - The Longest Permitted BUDs Established for Category 1 CSPs

Beyond-Use Date Limits and Storage Conditions				
Controlled Room Temperature (20°C-25°C)	Refrigerated (2°C-8°C)			
≤ 12 hours	<u><</u> 24 hours			

Table 2: Compounded Sterile Preparations - The Longest Permitted BUDs Established for Category 2 CSPs

Preparation Characteristics		Storage Temperature		
Compounding Method	Sterility and Testing Performed and Passed	Controlled Room Temperature (20°C-25°C)	Refrigerated (2°C-8°C)	Frozen (-25°C to -10°C)
Aseptically Processed Compounded Sterile Preparations (CSPs)	NO	Prepared from one or more non-sterile starting component(s) BUD: 1 day	Prepared from one or more non-sterile starting component(s) BUD: 4 days	Prepared from one or more non- sterile starting component(s) BUD: 45 days
		Prepared from only sterile starting component(s) BUD: 4 days	Prepared from only sterile starting component(s) BUD: 10 days	Prepared from only sterile starting component(s) BUD: 45 days
	YES	30 days	45 days	60 days
Terminally Sterilized Compounded Sterile Preparations (CSPs)	NO	14 days	28 days	45 days
	YES	45 days	60 days	90 days



MEDISCA® NETWORK INC. TECHNICAL SUPPORT SERVICES FORMULATION CHEMISTRY DEPARTMENT TOLL-FREE: 866-333-7811

TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

Addendum to the Assignment of Beyond-Use Dates for Sterile Preparations

Table 3: Compounded Sterile Preparations – The Longest Permitted BUDs Established for Category 3 CSPs

Preparation Characteristics	Storage Temperature		
Compounding Method	Controlled Room Temperature (20°C-25°C)	Refrigerated (2°C-8°C)	Frozen (-25°C to -10°C)
Aseptically processed, sterility tested, and passing all applicable tests for Category 3 CSPs	60 days	90 days	120 days
Terminally sterilized, sterility tested, and passing all applicable tests for Category 3 CSPS	90 days	120 days	180 days

• The BUD assigned to a Category 3 CSP <u>must</u> be supported by stability data obtained using a stability-indicating analytical method that is able to distinguish the active ingredient from its degradants and impurities (e.g., by forced degradation studies) and quantify the amount of the active ingredient.

Note: Medisca assigns Beyond-Use Date Limits for all sterile preparations based on the current USP BUD guidelines <u>at the time of formulation</u>. In the event that a particular formula's BUD does not match the current USP guidelines, the BUD section in the currently official version of USP-NF 2023, Issue 1 takes precedence.*

*Medisca has chosen to execute an early adoption of the revised standards of USP-NF 2023 (to be official 11/01/2023). Please check with your local regulatory body to confirm which standards are applicable to your practice.

For exceptional cases, certain formulations may be assigned a lower BUD than what is indicated within the USP guidelines due to specific stability information surrounding the formulation in question. In such instances, the assigned BUD within the formulation stands.

If additional information and/or clarification is required, please e-mail our Compounding Support Services Department at copoundingservices@medisca.net or call 1-866-333-7811.

REFERENCES

1. USP <797>. United States Pharmacopeia / National Formulary 2023. Rockville, MD. US Pharmacopeial Convention, Inc. 2023.

DISCLAIMER: THIS DOCUMENT IS COPYRIGHT© 2022 MEDISCA PHARMACEUTIQUE INC, MEDISCA NETWORK INC., HEREBY REFERRED TO AS "THE NETWORK", PROVIDES THIS INFORMATION AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF RECOGNIZED COMPENDIÁ, MANUFACTURERS' INSTRUCTIONS AND/OR OTHER AUTHORITATIVE SOURCES AND TEXTS. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST OR OTHER APPROPRIATELY STATE LICENSED PROFESSIONAL. ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. THE PHARMACIST OR OTHER APPROPRIATELY STATE LICENSED PROFESSIONAL MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE STABILITY OF THE RESULTING FORMULATION, THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS DOCUMENT. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST OR OTHER APPROPRIATELY STATE LICENSED PROFESSIONAL TO KNOW THE LAW, TO COMPOUND ANY FINISHED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW. MEDISCA NETWORK INC. MAKES NO WARRANTIES WITH RESPECT TO INFRINGEMENT OR NON-INFRINGEMENT BY THE FORMULA OF ANY PATENT OR OTHER INTELLECTUAL PROPERTY OF ANY OTHER PARTY, AND IT IS THE RESPONSIBILITY OF THE PHARMACIST OR OTHER APPROPRIATELY STATE LICENSED PROFESSIONAL TO INVESTIGATE AND DETERMINE ANY SUCH ISSUE. IN ADDITION, THE NETWORK MAKES NO REPRESENTATIONS WHATSOEVER WITH RESPECT TO ANY THERAPEUTIC USES OR THE APPROPRIATENESS OF COMPOUNDED MEDICATIONS FOR ANY MEDICAL CONDITION, WHICH IS SOLELY THE JUDGMENT AND RESPONSIBILITY OF THE MEDICAL PRACTITIONER OR OTHER APPROPRIATELY STATE LICENSED PROFESSIONAL.